Search results for "Lip"

showing 10 items of 8306 documents

Lipoma of the fossa femoralis mimicking a femoral hernia. Report of 2 cases

2018

Highlights • Femoral lipoma can be mistaken with femoral hernia. • Differential diagnosis between femoral lipoma and femoral hernia can result challenging. • The occurrence of femoral pain can lead to misinterpretation of the symptoms.

medicine.medical_specialtyChronic compressive damagesFossaDifferential diagnosiPhysical examinationAsymptomaticArticleChronic compressive damage03 medical and health sciences0302 clinical medicineFemoral maUltrasoundotorhinolaryngologic diseasesmedicinebiologymedicine.diagnostic_testbusiness.industryFemoral herniafungiUltrasoundfood and beveragesLipomabiology.organism_classificationmedicine.diseaseFemoral ringFemoral herniaSurgerybody regionsstomatognathic diseasesmedicine.anatomical_structureFemoral mass030220 oncology & carcinogenesisDifferential diagnosis030211 gastroenterology & hepatologySurgeryLipomaDifferential diagnosismedicine.symptombusinessInternational Journal of Surgery Case Reports
researchProduct

Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

2013

Non-alcoholic fatty liver disease (NAFLD) refers to a disease spectrum, ranging from mere hepatic steatosis to hepatic necroinflammation (NASH, non-alcoholic steatohepatitis). NASH often leads to fibrosis, which can progress to cirrhosis with a high risk of liver failure and hepatocellular carcinoma. The course of NAFLD is highly variable, and only a minority of patients (2-3%) progress to end-stage liver disease. However, due to a dramatic increase of the risk factors for NAFLD, that is obesity and insulin resistance/type 2 diabetes, that affect 15-30% and 7-15% of subjects, in most industrialized countries, respectively, NAFLD has become the most frequent liver disease and is even conside…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesmedicine.diseaseBioinformaticsdigestive systemdigestive system diseasesLiver diseaseEndocrinologyInsulin resistanceLipotoxicityInternal medicinemedicineSteatosisSteatohepatitisMetabolic syndromebusinessJournal of Gastroenterology and Hepatology
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

Neurophysiological changes and chronic pain in cleft patients

2019

Abstract The aim of this study was to evaluate if patients after orofacial cleft repair experience neurophysiological changes with consecutive chronic pain states after surgery. Patients (n = 48) with a repaired orofacial cleft (CLP) recruited in a support group took part in a survey including five questionnaires. They revealed pain states, described cleft situation and history, and epidemiological data. Patients' quality of life and psychological comorbidity after the surgical procedures were assessed with the Oral Health Impact Profile (OHIP), the Giessen Subjective Complaints List (GSCL) and the Hospital Anxiety and Depression Scale (HADS). Furthermore, psychosocial impairment was docume…

medicine.medical_specialtyCleft LipPsychological interventionAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesmedicineHumansChildDepression (differential diagnoses)Depressionbusiness.industryChronic pain030206 dentistrymedicine.diseaseComorbidityOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisQuality of LifePhysical therapyAnxietySurgeryChronic PainOral Surgerymedicine.symptombusinessPsychosocialJournal of Cranio-Maxillofacial Surgery
researchProduct

Complement activation by oxidatively modified low-density lipoproteins

1999

Background Oxidatively modified low-density lipoproteins (LDLs) have been implicated in the pathogenesis of atherosclerosis and are found in human vascular lesions. There is increasing evidence that complement activation may also play a role in atherogenesis. Activated complement proteins have been demonstrated to be present in early atherosclerotic lesions, and lipids isolated from lesions have been shown to activate complement, hence their designation as lesion complement activator (LCA). The question now arose whether oxidized LDLs would also activate complement. Material and methods The complement-activating capacity of a lesion complement activator preparation and of minimally as well …

medicine.medical_specialtyClinical BiochemistryInflammationImmunoelectrophoresis030204 cardiovascular system & hematologyBiochemistryLipid peroxidationPathogenesisLesion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryVascular diseaseGeneral Medicinemedicine.diseaseComplement systemComplement (complexity)EndocrinologyBiochemistrylipids (amino acids peptides and proteins)medicine.symptomEuropean Journal of Clinical Investigation
researchProduct

Recent advances on stearoyl-Coa desaturase regulation in fatty liver diseases.

2012

Stearoyl-CoA desaturase 1 (SCD-1) is a delta-9 fatty acid desaturase that catalyzes the synthesis of monounsaturated fatty acids. Indeed, SCD-1 is the critical control point regulating hepatic lipogenesis and lipid oxidation. Due to its central role in lipid metabolism in the liver, recent studies have focused on the involvement of SCD-1 in the development of fatty liver during obesity, diabetes mellitus, hypertension, excessive alcohol consumption, and in subjects with high triglyceride blood concentrations. The accumulation of fat in liver cells can be a sign that harmful conditions are developing, possibly associated with or leading to inflammation of the liver. This review evaluates the…

medicine.medical_specialtyClinical Biochemistrychemistry.chemical_compoundLipid oxidationInternal medicineDiabetes mellitusmedicineAnimalsHumansPharmacologyTriglyceridebiologyFatty liverLipid metabolismmedicine.diseaseFatty LiverStearoyl-CoA DesaturaseEndocrinologyFatty acid desaturasechemistrybiology.proteinFatty Acids UnsaturatedSteatosisStearoyl-CoA DesaturaseFatty Liver AlcoholicTranscription FactorsCurrent drug metabolism
researchProduct

Effect of the stable prostacyclin analogue iloprost on water and electrolyte transfer of the rat ileum and colon in vivo.

1988

The effect of iloprost on water and ion transfer was measured simultaneously in tied-off loops of the rat ileum and colon in vivo. (1) In the ileal loops iloprost had no effect on water and ion transfer neither by intraluminal, nor intraaortal or intravenous application. (2) In the colonic loops only intraaortal bolus application of the high dose of 500 micrograms iloprost significantly decreased net water, sodium and chloride absorption, but did not induce net secretion. (3) Inhibition of endogenous prostaglandin synthesis by indomethacin did not change net water and electrolyte transfer in the ileum and colon. (4) Under this pretreatment i.v.-application of 100 micrograms iloprost, ineffe…

medicine.medical_specialtyColonSodiumClinical BiochemistryIndomethacinchemistry.chemical_elementProstaglandinEndogenyIleumProstacyclinBiochemistrychemistry.chemical_compoundChloridesIn vivoIleumInternal medicinemedicineAnimalsIloprostReceptorSodiumRats Inbred StrainsGeneral MedicineWater-Electrolyte BalanceEpoprostenolRatsmedicine.anatomical_structureEndocrinologychemistrycardiovascular systemPotassiumlipids (amino acids peptides and proteins)Iloprostmedicine.drugEuropean journal of clinical investigation
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct